Search results “Rheumatoid arthritis test detects levaquin damage”
RELENT... for a safer and more effective treatment of patients who suffer from autoimmunity
Find out more: www.relent.eu RELENT: RELapses prevENTion in chronic autoimmune disease: common mechanisms and co-morbidities The central question in RELENT is: Given the increasing number of treatment options becoming available, how can we determine which treatment is best for which patient? The RELENT consortium is working on chronic immune-mediated diseases, such as vasculitis, rheumatoid arthritis and inflammatory bowel disease. In all these diseases, the body’s own immune system attacks otherwise healthy tissue by mistake, leading to different pathologies. With our current knowledge, it is not possible to titrate the intensity of treatment to the individual need of the patient. RELENT aims to change this allowing for the first time the application of precision medicine to autoimmunity - a concept already well established in cancer treatment. This video gives an overview over the RELENT project, its content and vision from the perspective of the project coordinator, one of the RELENT scientists and a patient representative. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 668036 (RELENT). Twitter: https://twitter.com/RELENT_EU LinkedIn: https://www.linkedin.com/in/relent-project/
Views: 279 ARTTIC